C-reactive protein: The pawn has been promoted to queen

Current Atherosclerosis Reports

Volumn 5, Issue 2, 2003, Pages 101-105

  Yeh, Edward T H ^a   Palusinski, Robert P ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ACUTE PHASE PROTEIN; C REACTIVE PROTEIN; CERIVASTATIN; ESTROGEN; INTERLEUKIN 1BETA; INTERLEUKIN 6; METHYLPREDNISOLONE; MEVINOLIN; PRAVASTATIN; TUMOR NECROSIS FACTOR ALPHA; BIOLOGICAL MARKER; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT;

ALCOHOL WITHDRAWAL; ALZHEIMER DISEASE; ATHEROGENESIS; BIOCHEMISTRY; CARDIOVASCULAR DISEASE; CHROMOSOME 1; CLINICAL RESEARCH; CONGESTIVE CARDIOMYOPATHY; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DISEASE COURSE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HORMONE SUBSTITUTION; HOST RESISTANCE; HUMAN; INFLAMMATION; INSULIN RESISTANCE; MULTIINFARCT DEMENTIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PERCUTANEOUS CORONARY INTERVENTION; PROTEIN LOCALIZATION; PROTEIN STABILITY; PROTEIN SYNTHESIS; RECURRENCE RISK; REPRODUCIBILITY; REVIEW; RISK ASSESSMENT; RISK MANAGEMENT; SLEEP APNEA SYNDROME; SMOKING CESSATION; STROKE; THROMBOCYTE AGGREGATION INHIBITION; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS; WEIGHT REDUCTION; BIOSYNTHESIS; BLOOD; CORONARY ARTERY ATHEROSCLEROSIS; DRUG EFFECT; ESTROGEN THERAPY; FEMALE; RISK FACTOR;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CORONARY ARTERIOSCLEROSIS; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; RISK FACTORS;

EID: 0037983353     PISSN: 15233804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11883-003-0080-4     Document Type: Review

References (57)

1. Tillett WS, Francis T Jr: Serological reactions in pneumonia with a non-protein somatic fraction of pneumonococcus. J Exp Med 1930, 52:561-571.
2. Thompson D, Pepys MB, Wood SP: The physiological structure of human C-reactive protein and its complex with phosphocholine. Structure Fold Des 1999, 7:169-177.
3. Ganter U, Arcone R, Toniatti C, et al.: Dual control of C-reactive protein gene expression by interleukin-1 and interleukin-6. Embolism J 1989, 8:3773-3779.
4. Gabay C, Kushner I: Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999, 340:448-454.
5. Zee RY, Ridker PM: Polymorphism in the human C-reactive protein (CRP) gene, plasma concentrations of CRP, and the risk of future arterial thrombosis. Atherosclerosis 2002, 162:217-219.
6. Vickers MA, Green FR, Terry C, et al.: Genotype at a promoter polymorphism of the interleukin-6 gene is associated with baseline levels of plasma C-reactive protein. Cardiovasc Res 2002, 53:1029-1034.
7. Yasojima K, Schwab C, McGeer EG, et al.: Generation of C-reactive protein and complement components in atherosclerotic plaques. Am J Pathol 2001, 158:1039-1051.
8. Ockene IS, Matthews CE, Rifai N, et al.: Variability and classification accuracy of serial high-sensitivity C-reactive protein measurements in healthy adults. Clin Chem 2001, 47:444-450.
9. Haverkate F, Thompson SG, Pyke SD, et al.: Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet 1997, 349:462-466.
10. Morrow DA, Rifai N, Antman EM, et al.: C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. Thrombolysis in Myocardial Infarction. J Am Coll Cardiol 1998, 31:1460-1465.
11. Liuzzo G, Biasucci LM, Gallimore JR, et al.: The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med 1994, 331:417-424.
12. Ueda S, Ikeda U, Yamamoto K, et al.: C-reactive protein as a predictor of cardiac rupture after acute myocardial infarction. Am Heart J 1996, 131:857-860.
13. Ridker PM, Rifai N, Pfeffer MA, et al.: Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1998, 98:839-844.
14. Chew DP, Bhatt DL, Robbins MA, et al.: Incremental prognostic value of elevated baseline C-reactive protein among established markers of risk in percutaneous coronary intervention. Circulation 2001, 104:992-997.
15. Rossi E, Biasucci LM, Citterio F, et al.: Risk of myocardial infarction and angina in patients with severe peripheral vascular disease: predictive role of C-reactive protein. Circulation 2002, 105:800-803.
16. Buffon A, Liuzzo G, Biasucci LM, et al.: Preprocedural serum levels of C-reactive protein predict early complications and late restenosis after coronary angioplasty. J Am Coll Cardiol 1999, 34:1512-1521.
17. Ridker PM: High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 2001, 103:1813-1818.
18. Ridker PM, Rifai N, Rose L, et al.: Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002, 347:1557-1565.
19. Abramson JL, Weintraub WS, Vaccarino V: Association between pulse pressure and C-reactive protein among apparently healthy US adults. Hypertension 2002, 39:197-202.
20. Pradhan AD, Manson JE, Rifai N, et al.: C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001, 286:327-334.
21. Tchernof A, Nolan A, Sites CK, et al.: Weight loss reduces C-reactive protein levels in obese postmenopausal women. Circulation 2002, 105:564-569.
22. Chung MK, Martin DO, Sprecher D, et al.: C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. Circulation 2001, 104:2886-2891.
23. Shamsuzzaman AS, Winnicki M, Lanfranchi P, et al.: Elevated C-reactive protein in patients with obstructive sleep apnea. Circulation 2002, 105:2462-2464.
24. Schmidt R, Schmidt H, Curb JD, et al.: Early inflammation and dementia: a 25-year follow-up of the Honolulu-Asia Aging Study. Ann Neurol 2002, 52:168-174.
25. Pai JK, Curhan GC, Cannuscio CC, et al.: Stability of novel plasma markers associated with cardiovascular disease: processing within 36 hours of specimen collection. Clin Chem 2002, 48:1781-1784.
26. Kaplan MH, Volanakis JE: Interaction of C-reactive protein complexes with the complement system. I. Consumption of human complement associated with the reaction of C-reactive protein with pneumococcal C-polysaccharide and with the choline phosphatides, lecithin and sphingomyelin. J Immunol 1974, 112:2135-2147.
27. Torzewski M, Rist C, Mortensen RF, et al.: C-reactive protein in the arterial intima: role of C-reactive protein receptor-dependent monocyte recruitment in atherogenesis. Arterioscler Thromb Vasc Biol 2000, 20:2094-2099.
28. Cermak J, Key NS, Bach RR, et al.: C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood 1993, 82:513-520.
29. Pasceri V, Willerson JT, Yeh ET: Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 2000, 102:2165-2168.
30. Pasceri V, Cheng JS, Willerson JT, et al.: Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation 2001, 103:2531-2534.
31. Verma S, Li SH, Badiwala MV, et al.: Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation 2002, 105:1890-1896.
32. Zwaka TP, Hombach V, Torzewski J: C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis. Circulation 2001, 103:1194-1197.
33. Verma S, Wang CH, Li SH, et al.: A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation 2002, 106:913-919.
34. Venugopal SK, Devaraj S, Yuhanna I, et al.: Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation 2002, 106:1439-1441.
35. Yeh ET, Anderson HV, Pasceri V, et al.: C-reactive protein: linking inflammation to cardiovascular complications. Circulation 2001, 104:974-975.
36. Pasceri V, Yeh ET: A tale of two diseases: atherosclerosis and rheumatoid arthritis. Circulation 1999, 100:2124-2126.
37. Lagrand WK, Niessen HW, Wolbink GJ, et al.: C-reactive protein colocalizes with complement in human hearts during acute myocardial infarction. Circulation 1997, 95:97-103.
38. Griselli M, Herbert J, Hutchinson WL, et al.: C-reactive protein and complement are important mediators of tissue damage in acute myocardial infarction. J Exp Med 1999, 190:1733-1740.
39. Szalai AJ, VanCott JL, McGhee JR, et al.: Human C-reactive protein is protective against fatal Salmonella enterica serovar typhimurium infection in transgenic mice. Infect Immun 2000, 68:5652-5656.
40. Xia D, Samols D: Transgenic mice expressing rabbit C-reactive protein are resistant to endotoxemia. Proc Natl Acad Sci U S A 1997, 94:2575-2580.
41. Zouki C, Beauchamp M, Baron C, et al.: Prevention of in vitro neutrophil adhesion to endothelial cells through shedding of L-selectin by C-reactive protein and peptides derived from C-reactive protein. J Clin Invest 1997, 100:522-529.
42. Ahmed N, Thorley R, Xia D, et al.: Transgenic mice expressing rabbit C-reactive protein exhibit diminished chemotactic factor-induced alveolitis. Am J Respir Crit Care Med 1996, 153:1141-1147.
43. Filep JG, Herman F, Kelemen E, et al.: C-reactive protein inhibits binding of platelet-activating factor to human platelets. Thromb Res 1991, 61:411-421.
44. Gershov D, Kim S, Brot N, et al.: C-reactive protein binds to apoptotic cells, protects the cells from assembly of the terminal complement components, and sustains an antiinflammatory innate immune response: implications for systemic autoimmunity. J Exp Med 2000, 192:1353-1364.
45. Liu S, Manson JE, Buring JE, et al.: Relation between a diet with a high glycemic load and plasma concentrations of high-sensitivity C-reactive protein in middle-aged women. Am J Clin Nutr 2002, 75:492-498.
46. Imhof A, Froehlich M, Brenner H, et al.: Effect of alcohol consumption on systemic markers of inflammation. Lancet 2001, 357:763-767.
47. Crook MA, Scott DA, Stapleton JA, et al.: Circulating concentrations of C-reactive protein and total sialic acid in tobacco smokers remain unchanged following one year of validated smoking cessation. Eur J Clin Invest 2000, 30:861-865.
48. Geffken D, Cushman M, Burke G, et al.: Association between physical activity and markers of inflammation in a healthy elderly population. Am J Epidemiol 2001, 153:242-250.
49. Siegel AJ, Stec JJ, Lipinska I, et al.: Effect of marathon running on inflammatory and hemostatic markers. Am J Cardiol 2001, 88:918-920.
50. Ikonomidis I, Andreotti F, Economou E, et al.: Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin. Circulation 1999, 100:793-798.
51. Ridker PM, Cushman M, Stampfer MJ, et al.: Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997, 336:973-979.
52. Ridker PM, Rifai N, Pfeffer MA, et al.: Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1999, 100:230-235.
53. Ridker PM, Rifai N, Clearfield M, et al.: Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001, 344:1959-1965.
54. Plenge JK, Hernandez TL, Weil KM, et al.: Simvastatin lowers C-reactive protein within 14 days: an effect independent of low-density lipoprotein cholesterol reduction. Circulation 2002, 106:1447-1452.
55. Azar RR, Rinfret S, Theroux P, et al.: A randomized placebo-controlled trial to assess the efficacy of antiinflammatory therapy with methylprednisolone in unstable angina (MUNA trial). Eur Heart J 2000, 21:2026-2032.
56. Gebbie A: Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative Randomized Controlled Trial. Writing Group for the Women's Health Initiative#10; Investigators. JAMA 2002, 288:321-333.
57. Lowe GD, Upton MN, Rumley A, et al.: Different effects of oral and transdermal hormone replacement therapies on factor IX, APC resistance, t-PA, PAI and C-reactive protein--a cross-sectional population survey. Thromb Haemost 2001, 86:550-556.